{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-097449","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.076816+00:00","generated_at":"2026-05-30T01:25:01.514663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ImmuCell reports Q3 2024 product sales up 11% to $6M; net loss narrows to $702k","bullets":["Product sales $6M in Q3 2024 vs $5.4M in Q3 2023 (+11%); 9-month sales $18.7M (+51% YoY).","Net loss $702k ($0.09/sh) vs $940k ($0.12/sh) in Q3 2023; 9-month loss $2.7M vs $4.6M.","Gross margin improved to 26% of sales in Q3 2024 from 23% in Q3 2023.","EBITDA turned positive to ~$119k in Q3 2024 from ($95k) in Q3 2023.","Cash increased to $3.8M from $979K at Dec 31, 2023; no line of credit drawn."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-097449","json":"https://secwatch.observer/filing/0001213900-24-097449.json","markdown":"https://secwatch.observer/filing/0001213900-24-097449.md","text":"https://secwatch.observer/filing/0001213900-24-097449.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390024097449/0001213900-24-097449-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390024097449/ea0221098-8k_immu.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:25:01.514663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}